Metastatic soft-tissue sarcoma (STS), a devastating disease, has a median overall survival of only 12–18 months. Until recently, therapeutic options were limited and relied primarily on the use of anthracycline-based chemotherapy. Over the past two decades, improvement in the knowledge of the biology of STS has allowed the investigation of new therapeutic strategies including new cytotoxic agents, epigenetic drugs, specific targeted therapies, and immunotherapeutic treatments.

中文翻译：

---

软组织肉瘤的新治疗策略

转移性软组织肉瘤（STS）是一种破坏性疾病，中位总生存期仅为12-18个月。直到最近，治疗选择仍然受到限制，并且主要依靠基于蒽环类药物的化学疗法的使用。在过去的二十年中，对STS生物学知识的改进允许研究新的治疗策略，包括新的细胞毒性剂，表观遗传药物，特异性靶向疗法和免疫疗法。